
Zenocutuzumab is effective in treating NRG1 fusion-positive cancers. In a Phase 2 study, 30% of patients with advanced NRG1 fusion cancers responded to zenocutuzumab, with a median response duration of 11.1 months. Responses were observed in various tumors, especially non-small-cell lung cancer (29%) and pancreatic cancer (42%). Progression-free survival was 6.8 months, with mostly mild adverse events. Zenocutuzumab demonstrates the potential for treating this challenging cancer subtype.
Like
Save
Share